US Patent 11260119 None
Patent 11260119 was granted and assigned to Pfizer Limited on March, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2024
Golden AI
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+449 characters)
Article
Patent abstract
In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+17 properties)
Infobox
Patent Inventor Names
Annaliesa Sybil Anderson0
Avvari Krishna Prasad0
Jason Arnold Lotvin0
Jianxin Gu0
Jin-Hwan Kim0
Justin Keith Moran0
Karen Kiyoko Takane0
Laurent Oliver Chorro0
Ling Chu0
Mark Edward Ruppen0
Nishith Merchant0
Robert G. K. Donald0
Rosalind Pan0
Scott Ellis Lomberk0
Srinivas Kodali0
Suddham Singh0
Wei Chen0
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
112601190
Date of Patent
March 1, 2022
0Patent Application Number
165344570
Date Filed
August 7, 2019
0Official Website
Patent Primary Examiner
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Mar, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11260119 None
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11260119
Date of patent
March 1, 2022
Patent application number
16534457
Date Filed
August 7, 2019
Patent primary examiner
Find more entities like US Patent 11260119 None
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
